Puissant Bénédicte, Barreau Corinne, Bourin Philippe, Clavel Cyril, Corre Jill, Bousquet Christine, Taureau Christine, Cousin Béatrice, Abbal Michel, Laharrague Patrick, Penicaud Luc, Casteilla Louis, Blancher Antoine
Laboratoire d'Immunologie, Hôpital Rangueil, 1 avenue Jean Poulhès, TSA 50032, Toulouse cedex 9, France.
Br J Haematol. 2005 Apr;129(1):118-29. doi: 10.1111/j.1365-2141.2005.05409.x.
Like mesenchymal stem cells from bone marrow (BM-MSCs), adipose tissue-derived adult stem cells (ADAS cells) can differentiate into several lineages and present therapeutical potential for repairing damaged tissues. The use of allogenic stem cells can enlarge their therapeutical interest, provided that the grafted cells could be tolerated. We investigate here, for the first time, the immunosuppressive properties of ADAS cells compared with the well-characterized immunosuppressive properties of BM-MSCs. ADAS cells did not provoke in vitro alloreactivity of incompatible lymphocytes and, moreover, suppressed mixed lymphocyte reaction (MLR) and lymphocyte proliferative response to mitogens. The impairment of inhibition when ADAS cells and BM-MSCs were separated from lymphocytes by a permeable membrane suggests that cell contact is required for a full inhibitory effect. Hepatocyte growth factor is secreted by both stem cells but, similar to interleukin-10 and transforming growth factor-beta (TGF-beta), the levels of which were undetectable in supernatants of MLR inhibited by ADAS cells or BM-MSCs, it did not seem implicated in the stem cell suppressive effect. These findings support that ADAS cells share immunosuppressive properties with BM-MSCs. Therefore, ADAS cell-based reconstructive therapy could employ allogenic cells and because of their immunosuppressive properties, ADAS cells could be an alternative source to BM-MSCs to treat allogenic conflicts.
与来自骨髓的间充质干细胞（BM-MSCs）一样，脂肪组织来源的成体干细胞（ADAS细胞）可以分化为多个谱系，并具有修复受损组织的治疗潜力。如果移植的细胞能够被耐受，使用同种异体干细胞可以扩大它们的治疗价值。我们首次在此研究ADAS细胞的免疫抑制特性，并与已充分表征的BM-MSCs的免疫抑制特性进行比较。ADAS细胞在体外不会引发不相容淋巴细胞的同种异体反应性，此外，还能抑制混合淋巴细胞反应（MLR）和淋巴细胞对有丝分裂原的增殖反应。当ADAS细胞和BM-MSCs通过可渗透膜与淋巴细胞分离时抑制作用减弱，这表明细胞接触对于充分的抑制作用是必需的。两种干细胞都会分泌肝细胞生长因子，但与白细胞介素-10和转化生长因子-β（TGF-β）类似，在被ADAS细胞或BM-MSCs抑制的MLR上清液中未检测到它们的水平，它们似乎与干细胞的抑制作用无关。这些发现支持ADAS细胞与BM-MSCs具有共同的免疫抑制特性。因此，基于ADAS细胞的重建治疗可以使用同种异体细胞，并且由于它们的免疫抑制特性，ADAS细胞可能是BM-MSCs的替代来源，用于治疗同种异体冲突。
